ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

13-valent pneumococcal vaccine

Also written as “13-valent pneumococcal conjugate vaccine”, “13-valent Pneumococcal Conjugate Vaccine” and “13vPnC”.

Its studies are mostly in Pneumococcal Infections · Pneumonia, Pneumococcal · Pneumonia · Influenza, Human · HIV Infections, led by 7 companies.

Drug page13-valent pneumococcal vaccine: every studyMany companies study it; this page follows only the 65 they lead. All 129 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Aug 27, 200865 company-led studies, 2 open or runningNext primary completion: Feb 15, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizerits history only570 open or runningphase 4since Aug 27, 2008Sep 19, 2005none ahead
CanSino Biologicsits history only31 open or runningphase 3since Apr 8, 2021Sep 18, 2019Feb 15, 2027phase 3 · NCT07017777
Beijing Minhai Biotechnologyits history only10 open or runningphase 4since Jan 8, 2024Jan 8, 2024none ahead
Fosun Pharma11 open or runningphase 3since Feb 26, 2023Feb 26, 2023none ahead
Sinovac Biotechits history only10 open or runningphase 1since Oct 13, 2021Oct 13, 2021none ahead
Walvax Biotechnologyits history only10 open or runningphase 3since Mar 31, 2016Mar 31, 2016none ahead
Wuhan BravoVaxits history only10 open or runningphase 1since Oct 24, 2022Oct 24, 2022none ahead

Also a collaborator on its studies: Liaoning Chengda Biotechnology.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Fosun Pharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 26, 2023First study: phase 3 study in Pneumococcal InfectionsFirst studyNCT05759520 · 1,800 enrolled · China

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“A pneumococcal conjugate vaccine containing 13 different strains of the bacterium Streptococcus pneumoniae, used in children and studied in immunocompromised patients for the prevention of pneumococcal disease”NCIt, by rule

Studies

The one study Fosun Pharma leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05759520Pneumococcal Infections · China3Active, not recruitingJun 30, 20251,800

How it is read

Names in the registry

  • “13-valent pneumococcal conjugate vaccine”, 23 entries
  • “13-valent Pneumococcal Conjugate Vaccine”, 20 entries
  • “13vPnC”, 9 entries
  • “13-valent pneumococcal conjugate vaccine (13vPnC)”, 8 entries
  • “PCV13”, 5 entries

Codes read as this program: PCV13I.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.